YARW (Yarrow Bioscience) Scaled Net Operating Assets: (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
8 GF Score
Price $32.99
View Full Analysis

What is Yarrow Bioscience Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Yarrow Bioscience's operating assets for the quarter that ended in Dec. 2025 was $ Mil. Yarrow Bioscience's operating liabilities for the quarter that ended in Dec. 2025 was $ Mil. Yarrow Bioscience's Total Assets for the quarter that ended in . 20 was $ Mil. Therefore, Yarrow Bioscience's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was .

Yarrow Bioscience Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience Scaled Net Operating Assets Chart

Yarrow Bioscience Annual Data
Trend Dec25
Scaled Net Operating Assets
-0.71

Yarrow Bioscience Semi-Annual Data
Dec25
Scaled Net Operating Assets -0.71

YARW vs : Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Yarrow Bioscience's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yarrow Bioscience Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Yarrow Bioscience's Scaled Net Operating Assets falls into.


YARW
8GF Score
Yarrow Bioscience Inc YARW
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Yarrow Bioscience's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: . 20 )
=(-)/
=

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

Yarrow Bioscience's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: . 20 )
=(-)/
=

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience Business Description

Comparable Companies
Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
8GF Score

Get the complete analysis for YARW

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.99
Price